E Fund Management Co. Ltd. Reduces Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

E Fund Management Co. Ltd. lowered its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 24.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 6,493 shares of the biotechnology company’s stock after selling 2,072 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Blueprint Medicines were worth $599,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its stake in shares of Blueprint Medicines by 1.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 266,744 shares of the biotechnology company’s stock valued at $13,396,000 after buying an additional 4,127 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Blueprint Medicines by 9.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,055 shares of the biotechnology company’s stock worth $605,000 after acquiring an additional 1,052 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Blueprint Medicines by 4.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,269 shares of the biotechnology company’s stock valued at $1,872,000 after purchasing an additional 1,417 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in shares of Blueprint Medicines by 12.3% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 464,321 shares of the biotechnology company’s stock valued at $23,318,000 after purchasing an additional 50,994 shares during the period. Finally, TD Asset Management Inc lifted its holdings in Blueprint Medicines by 65.2% during the 3rd quarter. TD Asset Management Inc now owns 316,304 shares of the biotechnology company’s stock worth $15,885,000 after purchasing an additional 124,792 shares in the last quarter.

Insider Buying and Selling

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 25,073 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total value of $2,188,371.44. Following the sale, the director now owns 176,050 shares of the company’s stock, valued at approximately $15,365,644. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Jeffrey W. Albers sold 25,073 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the sale, the director now directly owns 176,050 shares in the company, valued at approximately $15,365,644. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Christopher K. Murray sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total value of $500,000.00. Following the transaction, the insider now owns 24,495 shares of the company’s stock, valued at approximately $2,449,500. The disclosure for this sale can be found here. Insiders have sold a total of 104,123 shares of company stock valued at $9,554,679 over the last three months. 3.88% of the stock is owned by company insiders.

Blueprint Medicines Trading Up 0.2 %

NASDAQ BPMC traded up $0.23 during trading on Wednesday, hitting $108.78. 478,483 shares of the company’s stock traded hands, compared to its average volume of 774,819. The firm has a market cap of $6.66 billion, a P/E ratio of -22.62 and a beta of 0.65. The stock has a fifty day moving average of $92.44 and a two-hundred day moving average of $82.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. Blueprint Medicines Co. has a 12-month low of $43.89 and a 12-month high of $110.93.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, beating the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. Blueprint Medicines’s quarterly revenue was up 85.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.65) EPS. As a group, sell-side analysts expect that Blueprint Medicines Co. will post -5.38 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BPMC. Piper Sandler upped their price target on Blueprint Medicines from $78.00 to $104.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Leerink Partnrs upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating in a research note on Monday. Citigroup boosted their price target on shares of Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a research report on Friday, May 3rd. HC Wainwright increased their price objective on Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Finally, SVB Leerink raised Blueprint Medicines from an “underperform” rating to a “market perform” rating and lifted their price objective for the company from $50.00 to $97.00 in a research note on Monday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $100.31.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.